Arcutis Biotherapeutics (ARQT) Competitors $15.52 +0.03 (+0.19%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$15.40 -0.13 (-0.81%) As of 08/29/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARQT vs. GRFS, RVMD, RYTM, LEGN, RNA, AXSM, ABVX, NUVL, MRUS, and CRSPShould you be buying Arcutis Biotherapeutics stock or one of its competitors? The main competitors of Arcutis Biotherapeutics include Grifols (GRFS), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Avidity Biosciences (RNA), Axsome Therapeutics (AXSM), Abivax (ABVX), Nuvalent (NUVL), Merus (MRUS), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry. Arcutis Biotherapeutics vs. Its Competitors Grifols Revolution Medicines Rhythm Pharmaceuticals Legend Biotech Avidity Biosciences Axsome Therapeutics Abivax Nuvalent Merus CRISPR Therapeutics Arcutis Biotherapeutics (NASDAQ:ARQT) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability. Which has more volatility and risk, ARQT or GRFS? Arcutis Biotherapeutics has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Is ARQT or GRFS more profitable? Grifols has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -35.40%. Grifols' return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arcutis Biotherapeutics-35.40% -62.62% -25.16% Grifols N/A N/A N/A Which has stronger valuation and earnings, ARQT or GRFS? Grifols has higher revenue and earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcutis Biotherapeutics$196.54M9.47-$140.04M-$0.75-20.69Grifols$7.81B0.88$169.80M$1.178.52 Does the media prefer ARQT or GRFS? In the previous week, Arcutis Biotherapeutics had 3 more articles in the media than Grifols. MarketBeat recorded 5 mentions for Arcutis Biotherapeutics and 2 mentions for Grifols. Arcutis Biotherapeutics' average media sentiment score of 1.58 beat Grifols' score of 1.42 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Grifols 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ARQT or GRFS? Arcutis Biotherapeutics currently has a consensus target price of $19.80, suggesting a potential upside of 27.58%. Grifols has a consensus target price of $10.30, suggesting a potential upside of 3.31%. Given Arcutis Biotherapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Arcutis Biotherapeutics is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Grifols 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.60 SummaryArcutis Biotherapeutics and Grifols tied by winning 7 of the 14 factors compared between the two stocks. Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARQT vs. The Competition Export to ExcelMetricArcutis BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.86B$3.08B$5.69B$9.74BDividend YieldN/A2.28%6.64%4.48%P/E RatioN/A20.9283.1926.59Price / Sales9.47352.35515.16159.07Price / CashN/A43.5325.6628.92Price / Book11.509.7811.766.08Net Income-$140.04M-$54.01M$3.27B$265.93M7 Day Performance-1.08%0.10%1.13%0.36%1 Month Performance8.61%8.52%8.30%5.58%1 Year Performance42.65%7.03%62.26%19.67% Arcutis Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARQTArcutis Biotherapeutics2.4673 of 5 stars$15.52+0.2%$19.80+27.6%+42.6%$1.86B$196.54M0.00150Positive NewsGRFSGrifols3.5343 of 5 stars$9.82-3.3%$10.30+4.9%+6.7%$6.99B$7.81B8.3923,822News CoverageRVMDRevolution Medicines4.3447 of 5 stars$35.67-3.6%$69.92+96.0%-10.9%$6.92BN/A-7.93250News CoveragePositive NewsRYTMRhythm Pharmaceuticals3.4539 of 5 stars$99.20-3.9%$101.57+2.4%+118.1%$6.86B$130.13M-32.96140Positive NewsLEGNLegend Biotech3.6485 of 5 stars$34.60-2.7%$73.00+111.0%-39.7%$6.53B$627.24M-39.322,609Analyst RevisionRNAAvidity Biosciences3.0542 of 5 stars$45.27-2.3%$67.00+48.0%+5.9%$5.96B$10.90M-12.72190Positive NewsInsider TradeAXSMAxsome Therapeutics4.7903 of 5 stars$116.31-1.9%$178.00+53.0%+36.5%$5.91B$385.69M-22.94380Positive NewsInsider TradeABVXAbivax2.3868 of 5 stars$77.46+0.2%$92.33+19.2%+537.5%$5.84BN/A0.0061News CoveragePositive NewsNUVLNuvalent3.3516 of 5 stars$74.05-2.7%$118.91+60.6%-10.0%$5.49BN/A-15.1140News CoveragePositive NewsMRUSMerus2.0667 of 5 stars$65.74-2.6%$88.64+34.8%+29.1%$5.10B$36.13M-11.9537Positive NewsCRSPCRISPR Therapeutics3.5771 of 5 stars$54.13-0.3%$71.60+32.3%+8.6%$4.94B$37.31M-9.97460Analyst Revision Related Companies and Tools Related Companies GRFS Competitors RVMD Competitors RYTM Competitors LEGN Competitors RNA Competitors AXSM Competitors ABVX Competitors NUVL Competitors MRUS Competitors CRSP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARQT) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
